Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-S095012 PET biodistribution study in advanced solid tumors
NL-OMON52007Recruiting
- Sponsor
- Servier
- Start
- Dec 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of PRS-344 in Nonhematologic neoplasms (3 arms), sponsored by Servier. Primary endpoints: Visual analysis of PET/CT scan images, Quantitative PET parameters for blood pool, organs, and tumor lesions and 5 more. Started Dec 2022; status: recruiting.
02
Drugs
PRS-344
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON52007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52007.